Pharmaceuticals, Biotechnology and Life Sciences
Horizon Pharma has announced that the Phase 3 trial, Steadfast (Safety, Tolerability and Efficacy of Actimmune Dose Escalation in Friedreich’s Ataxia study), evaluating Actimmune (interferon gamma-1b) for…
Horizon Pharma has announced its third-quarter 2016 financial results on Monday.
Horizon Pharma has completed the acquisition of Raptor Pharmaceutical…
Horizon Pharma plc has entered a definitive agreement to acquire Crealta Holdings LLC for $510 million in cash.
Horizon Pharma and its affiliate, Horizon Therapeutics, has gotten the European Commission’s (EC’s) approval for Ravicti – glycerol phenylbutyrate – Oral Liquid for use as an adjunctive therapy for chronic management patients with six subtypes of Urea Cycle Disorders (UCDs).
Judge Peter Kirwan of the Superior Court of California for the County of Santa Clara has granted Depomed motion for…
Dublin-based Horizon Pharma has provided an update on shareholders meeting related to the proposed acquisition of Depomed, Inc., according to which shareholders approved the issuance of up to 81,706,881 ordinary shares of Horizon Pharma plc, in connection with an acquisition of Depomed, Inc.
Horizon Pharma about Express Scripts’ business practices: “Express Scripts… also operates its own mail-order pharmacy and thus is a direct competitor of small, independent specialty pharmacies”